Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 8/20 | 0.47 |
| ▸ | CA2 | P00918 | 8/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | BCL9 | O00512 | 1/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28698992 | 0.84 | CA1 (0.56) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL17019166 | 0.82 | CA2 (0.52) | CA1CA2CA9CA12CA7 | |
| SCHEMBL14704102 | 0.82 | GAA (0.53) | GAAATMMGLLMEN1KMT2A | |
| SCHEMBL14106630 | 0.81 | NPC1 (0.68) | CA1CA2CA9MEN1KMT2A | |
| SCHEMBL17022164 | 0.80 | BCL9 (0.49) | GAACA1CA2CA9CA12 | |
| SCHEMBL4430377 | 0.79 | KMT2A (0.66) | GAAATMMGLLMEN1KMT2A | |
| SCHEMBL13397217 | 0.77 | GAA (0.71) | GAAATMMEN1KMT2ATRPV1 | |
| SCHEMBL8535425 | 0.76 | CA2 (0.65) | CA1CA2CA9CA12MEN1 | |
| 4-Nitrophenyl Phenylcarbamate SCHEMBL1434931 | 0.76 | ALDH1A1 (0.62) | GAAATMMGLLMEN1KMT2A | |
| SCHEMBL14542791 | 0.75 | TRPV1 (0.55) | GAAATMMGLLMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783513-B2 | STAT3 inhibitors and their anticancer use | OHIO STATE INNOVATION FOUNDATION (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783513-B2 | STAT3 inhibitors and their anticancer use | OHIO STATE INNOVATION FOUNDATION (US) | 2017-10-10 | — | — | US | disclosed |
| US-20150232434-A1 | STAT3 INHIBITORS AND THEIR ANTICANCER USE | OHIO STATE INNOVATION FOUNDATION | 2015-08-20 | — | — | US | disclosed |
| US-20150232434-A1 | STAT3 INHIBITORS AND THEIR ANTICANCER USE | OHIO STATE INNOVATION FOUNDATION | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232434-A1 | STAT3 INHIBITORS AND THEIR ANTICANCER USE | STAT3, STAT1, JAK1 | GAA 2240/4885CA1 1668/4885CA2 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.